Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent from parent or legal guardian prior to participation~2. Patients \> 5 and \< 12 years of age with open growth plates at time of enrollment~3. Tanner stage of 2 or less indicating pre-pubescence~4. Documented history of HPP, as evidenced by:~   * Presence of HPP-related rickets on skeletal radiographs of the wrist and knee~  * Serum alkaline phosphatase (ALP) below age-adjusted normal range~  * Plasma PLP at least twice the upper limit of normal~5. 25(OH) vitamin D level \> 20 ng/mL~6. Ability of patient and parent/guardian to comply with study requirements~Exclusion Criteria:~1. Serum calcium or phosphorus below age-adjusted normal range~2. History of sensitivity to any study drug constituent~3. Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities~4. Treatment with an investigational drug within 1 month before start of study drug~5. Current enrollment in any other study involving an investigational new drug, device, or treatment for HPP (e.g., bone marrow transplantation)~6. Current evidence of a treatable form of rickets~7. Prior treatment with bisphosphonates~8. Bone fracture or orthopedic surgery within the past 12 months that, in the opinion of the Investigator would interfere with the ability of study patient to comply with study protocol~9. Major congenital abnormality other than those associated with HPP

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- 2 mg/kg (Type: ACTIVE_COMPARATOR): 2 mg/kg subcutaneous injection three times per week.
- 3 mg/kg (Type: ACTIVE_COMPARATOR): 3 mg/kg subcutaneous injection three times per week.

Based on this trial design, predict the completion outcome and termination type (if applicable).